Telo Genomics Announces Termination of Investor Relations Agreement

Rhea-AI Summary

Telo Genomics (OTCQB:TDSGF) announced the termination of its investor relations consulting agreement with Sheridan Adams, effective June 12, 2026. The engagement, originally disclosed March 31, 2026, was understood by both parties to be a short-term, transitory role. Telo Genomics extended best wishes to Sheridan.

News Market Reaction – TDSGF

-27.59%

-27.59% Session close to close

In the Jun 30 session, TDSGF declined 27.59%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vancouver, British Columbia--(Newsfile Corp. - June 26, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, announces that the investor relations consulting agreement with Sheridan Adams, LLC ("Sheridan"), as announced on March 31, 2026, has been terminated effective June 12, 2026. It was initially understood between the parties that this was a transitory role for Sheridan and was not intended to be long term. The Company wishes Sheridan well with its future endeavours.

About Telo Genomics

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit www.telodx.com.

For further information, please contact:
John Price
Chief Financial Officer
408-550-5767
info@telodx.com

555 Richmond Street West
Toronto, ON, Canada, M5V 3B1
www.telodx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual outcome to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303174

FAQ

What investor relations agreement did Telo Genomics (TDSGF) terminate in June 2026?

Telo Genomics terminated its investor relations consulting agreement with Sheridan Adams, effective June 12, 2026. According to Telo Genomics, this engagement had been understood by both parties as a transitory, short-term role rather than a long-term investor relations arrangement.

When did Telo Genomics (TDSGF) end its investor relations deal with Sheridan Adams?

Telo Genomics ended its investor relations consulting agreement with Sheridan Adams effective June 12, 2026. According to Telo Genomics, the agreement had originally been announced on March 31, 2026 and was intended from the outset to be a temporary, transitory role.

Why was the Telo Genomics (TDSGF) investor relations role with Sheridan Adams considered transitory?

The investor relations role with Sheridan Adams was considered transitory because both parties understood it was not intended as a long-term engagement. According to Telo Genomics, the consulting agreement was structured as a short-term role that has now been formally terminated.

Did Telo Genomics (TDSGF) give a reason for ending the Sheridan Adams investor relations agreement?

Telo Genomics stated that the investor relations agreement with Sheridan Adams was always understood as a transitory role. According to Telo Genomics, the engagement was not meant to be long term and has now concluded effective June 12, 2026.

What dates are important for the Telo Genomics (TDSGF) and Sheridan Adams IR agreement?

The investor relations agreement with Sheridan Adams was announced March 31, 2026 and terminated effective June 12, 2026. According to Telo Genomics, the consulting role was intended from the start to be short term rather than an ongoing, long-term investor relations mandate.

Does the termination of the Sheridan Adams agreement change Telo Genomics (TDSGF) investor relations strategy?

The announcement only confirms termination of the consulting agreement and notes it was transitory. According to Telo Genomics, Sheridan’s role was not intended to be long term, and the company simply wished Sheridan well in its future endeavours.